Medical weight management — treating weight as a health issue, not a willpower issue

About this guide

Weight is one of the hardest chronic conditions to talk about honestly in primary care. Patients arrive having been told to “just eat less and move more” — sometimes for years, sometimes by doctors who meant well but underestimated the biology. The underlying assumption is usually that weight is a willpower problem; the evidence says it is a medical problem that responds to medical treatment.

Medical weight management at KTMC is built around that premise. We take weight seriously as a health issue because it quietly drives so much else — type 2 diabetes, high blood pressure, kidney disease, fatty liver, obstructive sleep apnoea, osteoarthritis, several cancers, fertility problems, and the increased cardiovascular risk that sits underneath all of it. When weight changes, most of those change with it.

This guide covers:

• Why weight is a medical issue, not a moral or cosmetic one
• How we assess it — beyond the number on the scale
• What’s actually driving weight gain — biology, environment, and behaviour together
• The lifestyle foundation — what real, sustainable change looks like
• The medications we use, what they do, and what to realistically expect
• When bariatric surgery is the better option
• Common questions — is it cheating, will I regain, is it safe?

It sits alongside our cardiovascular-kidney-metabolic (CKM) guide, diabetes series, and cholesterol guide. Weight management is rarely an isolated project — for most of our patients, it is the upstream lever for all of them.

Weight as a medical issue — what it actually drives

Carrying significantly more weight than a body is designed for — particularly stored as visceral or ectopic fat (in the abdomen, liver, pancreas, muscle, heart) — affects almost every organ system. The short list of conditions where excess weight is a major driver or significant contributor:

• Type 2 diabetes and prediabetes — the single biggest driver locally
• High blood pressure
• Dyslipidaemia — particularly raised triglycerides and low HDL
• Chronic kidney disease
• Cardiovascular disease — coronary artery disease, heart failure, atrial fibrillation, stroke
• Metabolic dysfunction-associated steatotic liver disease (MASLD) — formerly called non-alcoholic fatty liver disease (NAFLD) — now the most common chronic liver disease in Singapore
• Obstructive sleep apnoea — increasingly common, often under-diagnosed, and bidirectionally linked to weight
• Gastro-oesophageal reflux
• Osteoarthritis — particularly of the knees and hips
• At least 13 cancers — including post-menopausal breast, colorectal, endometrial, kidney, oesophageal, pancreatic, liver, and gallbladder cancers
• Fertility problems in both men and women, polycystic ovary syndrome, gestational diabetes, and complications in pregnancy
• Depression, anxiety, and binge-eating disorder — often both a cause and a consequence
• Functional limitation — stamina, sleep quality, joint pain — that quietly erodes quality of life

That list is the reason treating weight often does more for a patient’s overall health than treating any one of the conditions it drives. A 10–15% weight reduction can normalise blood sugar in early type 2 diabetes, meaningfully reduce blood pressure, improve sleep apnoea, resolve fatty liver in many patients, and take years of cardiovascular risk off the trajectory.

How we assess it — beyond the number on the scale

Body weight on its own is a limited measure. In clinic we typically use several:

BMI — with Asian-adjusted thresholds

Body mass index (BMI = weight in kg divided by height in m²) is the starting point, but Singapore and other Asian populations use lower cut-offs than European reference data, because metabolic complications appear at lower BMIs:

A BMI of 25 — considered “just overweight” by Western criteria — is already a meaningful metabolic risk marker in an Asian patient.

When BMI doesn’t apply. BMI is a useful screening tool for most adults between 18 and 65 but doesn’t work in several groups:

• Under 18 — growth charts are used instead
• Pregnancy — weight change is expected and managed separately
• Very muscular individuals (e.g. athletes, bodybuilders) — a high BMI may reflect muscle rather than fat
• Older adults (65 and above) — we interpret BMI with prudence, paying more attention to weight trajectory, unintentional loss, muscle strength, and frailty rather than the number alone. Unintentional weight loss in an older adult is always worth investigating.

Waist circumference

BMI misses a crucial variable: where the weight is. Fat around the abdomen (visceral adiposity) is metabolically far more damaging than fat around the hips and thighs. A lean person with a large waist still carries substantial metabolic risk.

Singapore’s waist circumference thresholds:

• Men: ≥ 90 cm indicates increased risk
• Women: ≥ 80 cm indicates increased risk

Measure at the midpoint between the lower rib and the top of the hip bone, on bare skin, at the end of a normal breath out. No breath-holding.

Body composition

In selected patients we use bioelectrical impedance analysis (BIA) or similar to estimate body fat percentage, visceral fat rating, and muscle mass. This is useful when:

• BMI is borderline and the clinical question is genuinely whether excess adiposity is present (very muscular patients, older patients with reduced muscle)
• Tracking progress on treatment — because losing visceral fat while preserving muscle is a much better outcome than losing the same weight in muscle
• Screening for sarcopenic obesity in older patients (adequate fat but low muscle mass, which carries its own risk profile)

Metabolic workup

We usually check, at the first weight-focused visit:

• Fasting glucose and HbA1c
• Lipid panel
• Liver enzymes (ALT, AST, GGT) and sometimes a liver ultrasound if MASLD is suspected
• Thyroid function (TSH) — hypothyroidism is a reversible cause
• Kidney function (eGFR) and UACR
• Blood pressure
• Vitamin D — often low, often relevant for muscle and mood
• Consider a sleep study if obstructive sleep apnoea is likely (significant snoring, witnessed apnoeas, unrefreshing sleep, daytime fatigue)

This is a package that usually answers most clinical questions in one visit.

Metabolic syndrome — a specific pattern worth checking for

Across the assessment above we also look for metabolic syndrome — a specific cluster of findings that together carry higher risk of developing type 2 diabetes and cardiovascular disease than any one finding does on its own. By the Singapore-adjusted definition, you have metabolic syndrome when any three of the following five traits are present:

Meeting the definition doesn’t change treatment dramatically — the individual conditions get treated on their own merits — but it’s a useful summary of cardiometabolic risk, and it can motivate earlier action than any single threshold crossing would.

The target we aim for

For most patients with BMI ≥ 23 kg/m² or a high-risk waist circumference, a reasonable first-phase goal is to reduce body weight by 5 to 10% over 6 to 12 months, achieved through a combination of lifestyle change and — where appropriate — medication.

Why 5–10%? Because that is the weight reduction at which most of the metabolic wins show up:

• Meaningful reduction in blood pressure
• Improvement in lipid profile
• Substantial improvement in blood sugar and insulin sensitivity
• Reduction in fatty liver
• Reduced progression of obstructive sleep apnoea
• Often enough to take early type 2 diabetes into remission or delay progression from prediabetes

Many patients, especially those on the newer medications, end up achieving more. But the first 5–10% is where the bulk of the metabolic benefit sits, and it’s a realistic target for most patients. Rapid loss beyond this is not the goal; durable loss is.

What’s actually driving weight gain

It’s worth being honest about this, because the “willpower framing” has caused genuine harm.

Biology carries most of the load

Body weight is tightly regulated. Appetite, satiety, metabolic rate, fat storage, and energy expenditure are coordinated by a network of hormones (leptin, ghrelin, GLP-1, PYY, GIP, insulin, cortisol), by the hypothalamus, by the gut microbiome, and by a deeply conserved biological drive to defend stored weight. When someone loses weight, the body actively resists further loss and promotes regain — lower metabolic rate, higher hunger, lower satiety — for many years.

This is why diets work in the short term and fail in the long term. It isn’t about willpower degrading; it’s about the body recalibrating its set point. The new generation of medications (GLP-1 receptor agonists, tirzepatide) work partly by shifting this set point, which is a fundamentally different mechanism from “eat less.”

Beyond that, genetics contribute substantially — monogenic obesity is rare, but polygenic predisposition is common, and body weight has significant heritability comparable to height.

Environment is the accelerant

On top of biology, the food environment in Singapore (and most of the developed world) is engineered to drive overeating. Ultra-processed foods are specifically designed for palatability, convenience, calorie density, and rapid consumption. The portion sizes, meal frequency, sugar content, and daily temptation pattern are meaningfully different from even 30 years ago. This isn’t a character defect in any particular patient; it’s a population-level environmental shift that no individual chose.

Other contributors worth naming

• Sleep deprivation and shift work dysregulate appetite hormones
• Chronic stress raises cortisol, which drives visceral fat
• Certain medications — insulin, some diabetes drugs (especially sulphonylureas, older insulins), several antipsychotics, some antidepressants, long-term oral corticosteroids, some blood-pressure medications, some contraceptives
• Hormonal conditions — hypothyroidism, polycystic ovary syndrome, Cushing’s syndrome (rare), pituitary issues (rare)
• Perimenopause and menopause — often accompanied by meaningful body composition change independent of food intake
• Life transitions — pregnancy, child-rearing, bereavement, job stress, illness — often anchor a new weight trajectory

Naming these matters because it helps the conversation move from “why can’t I lose weight?” to “what’s actually driving this, and what’s likely to work?”

The lifestyle foundation — what sustainable change looks like

Medication without lifestyle change works poorly. Lifestyle change without medication often works for a while and then fails. For most patients, the right answer is both, configured realistically.

Food pattern

Rather than a specific named diet, we look for a sustainable pattern that most patients can keep going for years. The best-evidenced framework is a plant-forward, Mediterranean or DASH-style (Dietary Approaches to Stop Hypertension) pattern, locally adapted:

• More vegetables — at least half of most plates
• Reasonable carbohydrate portions — smaller portions of rice, noodles, bread; brown rice, quinoa, oats where palatable; reduce sugary drinks
• Protein at every meal — fish, tofu, eggs, lean meat, dairy, beans. Higher protein intake supports muscle preservation during weight loss.
• Healthy fats — olive oil, avocado, nuts, fatty fish
• Less ultra-processed food — the biggest practical lever in most people’s diets
• Honest about alcohol — empty calories, disinhibits food choices, disrupts sleep

What doesn’t matter as much as it’s often made to:

• Specific macronutrient ratios — very-low-carb, Mediterranean, DASH, plant-based, intermittent fasting patterns all produce similar long-term outcomes if adhered to. The best diet for you is the one you can sustain.
• “Cleanses,” juice diets, extreme restriction — short-term weight loss, high rebound rate, usually counterproductive
• Supplements marketed for weight loss — very limited evidence; some unsafe

Physical activity

• 150–300 minutes per week of moderate-intensity activity — brisk walking, cycling, swimming
• 2 sessions per week of resistance training — particularly important during weight loss to preserve muscle
• Sitting less throughout the day — standing desks, walking meetings, stairs
• Activity that you’ll keep doing > activity that looks best on paper

Weight loss with medication without any exercise is still meaningful for metabolic outcomes, but adding activity protects muscle, improves cardiometabolic markers further, supports mood, and improves sleep.

A note on starting exercise at higher BMIs or with comorbidities. For patients with BMI in the higher-risk ranges (≥ 27.5 with comorbidities, or ≥ 32.5), we’d usually do an exercise pre-participation assessment before recommending structured programmes — checking blood pressure, heart rate response, any symptoms on exertion, joint issues, and medications that might affect exercise response. This isn’t a barrier to moving; it’s making sure the movement you do is safe for you. For lower-risk patients, a self-administered tool such as the Get Active Questionnaire or PAR-Q is usually enough.

Sleep

• 7–9 hours per night is a weight management intervention
• Screen for obstructive sleep apnoea in anyone with significant snoring, witnessed apnoeas, daytime sleepiness, or resistant hypertension — OSA both worsens weight gain and improves with weight loss

Behaviour and stress

• Mindful eating — not a gimmick; helps disentangle physical hunger from stress, boredom, or emotional triggers
• Cognitive behavioural approaches to eating patterns — genuinely evidence-based for many patients, especially those with binge-type patterns
• Stress management — chronic stress drives cortisol, which drives visceral fat, which drives insulin resistance
• Honest assessment of food environment at home and work — what’s in easy reach usually gets eaten

Alcohol and smoking

• Alcohol: empty calories, disinhibits food choices, disrupts sleep. Moderate limits (no more than 2 standard drinks per day for men, 1 for women; less is better) — or consider a break during the weight-change phase.
• Smoking: weight management is an excellent reason not to start, but quitting is rarely the right time to combine with aggressive weight loss. We time these interventions thoughtfully.

When medication is appropriate

There’s no rule saying everyone above a BMI threshold needs medication. Equally, there’s no rule saying medication is only for the severely affected. The clinical question is whether the benefit outweighs the risks and costs in this particular patient.

Medication is usually appropriate to discuss when:

• BMI is ≥ 27.5 (Asian cut-off for obesity)
• BMI is 23–27.4 plus a weight-related condition — type 2 diabetes, prediabetes, hypertension, dyslipidaemia, MASLD, CKD, obstructive sleep apnoea, significant osteoarthritis
• Lifestyle change alone has been given a fair trial (usually 3–6 months of structured effort) without achieving target
• The biology is clearly unfavourable — strong family history, previous weight trajectory, metabolic findings — and waiting is probably not the best strategy

It is less appropriate when:

• BMI and metabolic picture are within the low-risk range
• The patient’s relationship with food and body image makes medicalising the issue likely to cause harm (some patients with histories of restrictive eating disorders)
• Pregnancy or planning pregnancy
• The cost is genuinely unaffordable and would displace more important treatments

We don’t prescribe weight medications without a proper conversation first. This is a clinical decision, not a transaction.

The medications we use

The landscape has changed dramatically in the last five years. The centre of gravity has shifted to the incretin-based therapies — GLP-1 receptor agonists and tirzepatide — because their effect size is substantially larger than anything we had before.

GLP-1 receptor agonists

These medications mimic a natural gut hormone (glucagon-like peptide-1) released after eating. They slow stomach emptying, increase satiety, reduce appetite, and — importantly — reset the brain’s set point for body weight. In Singapore for weight management, we use:

• Semaglutide — Wegovy (weight-management branding). Weekly subcutaneous injection, titrated up over several months. Typical weight loss with optimal dose is around 15% of body weight over 68 weeks in trial populations.
• Liraglutide — Saxenda (weight-management branding). Daily subcutaneous injection. Typical weight loss around 8–10%.

These are the same active molecules as Ozempic and Victoza respectively, which are registered for diabetes — the weight-management branding differs because the dosing and indication differ.

What they do well:

• Substantial weight loss that is sustained while continued
• Cardiovascular benefit in high-risk patients (particularly semaglutide)
• Improvement in glucose, lipids, blood pressure, fatty liver, and sleep apnoea
• Relatively well-tolerated for most patients once titrated in

Common side effects:

• Nausea — usually worst in the first few weeks of a new dose, usually improves. Slow titration helps.
• Constipation, heartburn, early satiety
• Occasional vomiting — usually with larger meals or fatty foods
• Rare but important: pancreatitis (stop if severe abdominal pain), gallstones (particularly with rapid weight loss), rare gastroparesis

Points worth knowing:

• Titration matters — starting dose is low and increased gradually to reduce nausea
• Sick-day behaviour — if you’re acutely unwell, vomiting, or unable to eat normally, hold the next dose and contact us
• Injection technique is straightforward — we teach it in clinic; our diabetes injectables guide covers the specifics
• Long-term — these medications work while taken. Stopping usually results in partial or complete regain over 12–18 months in most patients. The honest framing is that obesity is a chronic condition and this is chronic treatment.

Tirzepatide — Mounjaro / Zepbound

A newer medication that activates two gut hormone receptors — GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). Weekly subcutaneous injection. Trial weight loss at highest dose is around 20–22% of body weight — the largest effect seen from any pharmacotherapy.

• Mounjaro — the diabetes brand (registered in Singapore)
• Zepbound — the same drug marketed for weight management; registration and availability in Singapore continue to evolve, so we’d confirm current status and supply at your visit

Side-effect profile is similar to GLP-1 alone — mainly gastrointestinal, particularly during titration.

Orlistat (Xenical)

A longer-established weight medication that works locally in the gut — inhibiting pancreatic lipase, which reduces absorption of dietary fat. Typical weight loss around 3–5% of body weight; modest compared to the incretins but still clinically meaningful for some patients.

Side effects are directly related to fat intake — oily stools, flatulence, urgency, occasionally fat-soluble vitamin deficiency with long use. Patients who adopt a lower-fat diet both lose more weight and have fewer side effects.

Orlistat is available at lower cost than the injectable options and is still a reasonable choice for patients who want oral therapy, can’t afford or don’t wish to inject, or don’t tolerate GLP-1-based options.

What we generally don’t recommend

• “Compounded GLP-1 peptides” — these are unregulated preparations, often sold online or through non-medical channels, with variable and sometimes poor-quality active ingredient. We don’t recommend them.
• Unregulated weight-loss supplements — green tea extract mega-doses, garcinia cambogia, “fat burner” stacks, unlabelled herbal preparations. Evidence ranges from weak to harmful; some have been associated with severe liver injury.
• Very-low-calorie diet (VLCD) programmes without medical supervision — 800 kcal/day programmes can work, but they are medical interventions and should be supervised. “Meal replacement” purchases from non-medical sources often aren’t.
• Sibutramine (Reductil) and fenfluramine-phentermine combinations — withdrawn globally and from Singapore. If you’re offered anything under these names, it’s not legitimate.

If you’re taking anything we haven’t prescribed that’s marketed for weight loss — prescription, OTC, herbal, supplement — please bring the packaging to your next visit. We’d rather know than be surprised.

Bariatric and metabolic surgery — when it’s the better option

For patients with significant obesity (particularly BMI ≥ 32.5 with metabolic comorbidities, or ≥ 37.5 alone — using the Asian-adjusted thresholds used in Singapore), bariatric and metabolic surgery often produces more durable weight loss and more complete remission of obesity-related conditions than medication alone.

Common procedures:

• Laparoscopic sleeve gastrectomy — the most commonly performed in Singapore; 70–80% of the stomach removed
• Roux-en-Y gastric bypass — rearranges the anatomy so food bypasses part of the stomach and upper small intestine
• Gastric band — fallen out of favour; higher complication and revision rates; not generally used now

Typical weight loss is around 25–30% of body weight at 1–2 years, with substantial long-term durability. Type 2 diabetes remission rates are significant for many patients. The trade-offs include surgical risk, lifelong follow-up and supplementation (vitamin B12, iron, calcium, vitamin D), a permanent change in how eating works, and the need for robust psychological support through the transition.

Bariatric surgery is a specialist-led pathway — we work with local bariatric teams and refer appropriately. If you think you might qualify, we can discuss eligibility, realistic outcomes, and the assessment process.

A practical point: the newer medications have changed when surgery is the best option. Some patients who would once have gone straight to surgery now achieve similar outcomes on tirzepatide alone, at least in the medium term. For others, surgery remains the better choice. This is a decision we make with you, not for you.

Common questions

“Is taking medication for weight a form of cheating?”

This is one of the most common questions — and the answer is no. You are not cheating; you are treating a medical condition that responds to treatment. The moral framing of weight is a cultural artefact of a past era. No one asks whether treating high blood pressure with medication is “cheating.”

The practical test is simple: if medication improves your health, your quality of life, and your long-term trajectory, then it’s appropriate treatment. How you feel about the use of medication is worth talking through, but it’s not a medical reason to avoid effective treatment.

“Will I regain weight if I stop?”

For most patients, yes — at least partially. Studies of semaglutide, tirzepatide, and related medications consistently show substantial weight regain over 12–18 months after stopping, because the underlying biology reverts.

The honest framing is that obesity is a chronic condition and this is chronic treatment. We’d give the same answer about blood-pressure medication — stopping it means blood pressure usually goes back up. The question isn’t really “can I stop eventually” but “does the benefit-to-cost balance justify continuing?”

That said — what has been gained during treatment doesn’t entirely disappear. Metabolic improvements often outlast the weight itself. Eating patterns and habits established during treatment can persist. Some patients do maintain after stopping; many don’t.

“Is it safe long-term?”

The incretin-based medications have a safety record of roughly 15–20 years now (liraglutide was first approved in 2010; semaglutide in 2017; tirzepatide in 2022). Major international pharmacovigilance programmes continue to monitor for rare effects.

What we know:

• Cardiovascular safety is reassuring; in fact, semaglutide has shown cardiovascular benefit in high-risk patients
• Kidney safety is favourable, with emerging benefit
• Pancreatitis is uncommon but possible — severe abdominal pain is a stop-and-call-us signal
• Gallstones occur more commonly with rapid weight loss (not specific to these medications)
• Thyroid C-cell tumour signal seen in rodent studies has not translated into human populations at clinically meaningful rates, but personal or family history of medullary thyroid cancer or MEN2 is a reason to avoid these agents
• There are ongoing questions around very long-term muscle preservation, particularly in older patients

Side effects that make patients stop most often are gastrointestinal and dose-limiting rather than serious.

“How much does it cost?”

Honestly, this varies. The newer medications (Wegovy, Mounjaro/Zepbound) are currently expensive in Singapore; Saxenda is usually lower but still meaningful. MediSave coverage for weight-management medications is limited, and CHAS does not usually cover them for weight indications. For diabetes indications the same molecules are sometimes partially covered. We’ll be direct about cost at the initial conversation, including alternative cheaper options (orlistat, lifestyle-only, or surgery) where appropriate.

“Will I feel terrible on it?”

Most patients have some GI symptoms in the first 1–2 weeks after each dose increase. Slow titration, smaller meals, avoiding fatty or fried food, and not eating to “full” substantially reduce this. If side effects persist or are severe, we adjust.

“Can I lose weight without medication?”

Yes — some patients can, and lifestyle-only should always be trialled first where that’s reasonable. The question is less “can it be done” than “is this the most effective and sustainable path for you at this stage?” Some patients do very well with lifestyle alone; others have already tried that extensively and deserve more effective tools.

Long-term care and maintenance

The hardest part of weight management is not the losing; it is the keeping. The biology of regain is powerful. A reasonable long-term plan usually includes:

• Maintenance medication dose — often lower than the weight-loss phase dose
• Regular check-ins — quarterly for the first year, then 6–12 monthly if stable
• Ongoing monitoring of weight, waist, blood pressure, glucose, lipids, kidney function, liver enzymes
• Active muscle preservation — resistance training becomes more important as weight comes off
• A plan for life events — illness, surgery, travel, pregnancy, ageing — that would require adjustment
• Honest conversations when the plan isn’t working, rather than drifting

Small weight regain is common and rarely catastrophic. Large regain over a short period signals that something has changed and is worth a conversation rather than quiet self-blame.

The Singapore context — what’s available to you

Healthier SG and the weight-management pathway

Weight management sits within the broader preventive-care framework of Healthier SG. For patients enrolled with us, weight review is integrated into the chronic-care plan rather than treated as a separate project.

The national framework organises weight-management support along a spectrum from self-directed through to specialist-led:

• Self-directed activity and preventive programmes — the Healthy 365 (H365) app tracks steps, active minutes, and diet logging, and connects you with programmes from HPB, SportSG, and People’s Association. Suited to patients at low-to-moderate risk who are self-motivated and enjoy independent activity.
• Structured community weight-management programmes — for patients with moderate-to-high BMI or chronic conditions, these programmes include group sessions, lifestyle counselling, and exercise guidance. SportSG’s Active Health Manage Series (Metabolic and Musculoskeletal-Knee categories as of 2026) is the current structured programme pathway for our weight-focused patients.
• Primary Care Network (PCN) care teams — allied health counselling (nutrition, activity coaching) that we can involve in your care for more individualised lifestyle support
• Tertiary weight-management programmes — acute-hospital multidisciplinary obesity clinics for patients who need the most intensive intervention, usually those with BMI ≥ 32.5 with significant comorbidities or BMI ≥ 37.5 alone. Referral is led by the clinic.

Patients don’t have to navigate this alone. When we assess you, we’ll match you to whichever part of this pathway fits your picture — and adjust as things change.

Cost and subsidy

• MediSave coverage for weight-management-specific medications is limited — most weight indications are not MediSave-claimable. Some molecules, when used for diabetes, are partially claimable.
• CHAS similarly focuses on chronic disease medications rather than weight-indication prescriptions.
• HSA regulation is strict on unapproved weight-loss products. If a product is being sold outside of regulated pharmacies or clinics, it’s usually unregulated — bring it to us before taking it.
• Bariatric surgery is available in both public restructured hospitals and private centres; MediSave and insurance coverage vary widely and we’d help you think through the financial side as part of the referral conversation.

Get in touch

Joo Chiat — 172 Joo Chiat Road, #01-01, Singapore 427443 · Tel 6920 1952

Punggol — 658 Punggol East, #01-04, Singapore 820658 · Tel 6312 4589

Email — admin@ktmc.sg

References

Guidelines and consensus statements

• Ministry of Health, Singapore / Health Promotion Board. HPB–MOH Clinical Practice Guidelines 1/2016: Obesity.
• Ministry of Health, Singapore. Healthier SG Care Protocol — Body Mass Index (BMI) Control. Updated April 2026. primarycarepages.sg
• American Association of Clinical Endocrinology (AACE) / American College of Endocrinology. Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. aace.com
• The Obesity Society / American Heart Association / American College of Cardiology. AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults.
• Obesity Medicine Association. Obesity Algorithm 2024–2025. obesitymedicine.org
• WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157–163.
• Health Promotion Board Singapore. Metabolic Syndrome — patient and clinician resources. healthhub.sg

Landmark trials

• Wilding JPH, Batterham RL, Calanna S, et al. (STEP-1). Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989–1002.
• Pi-Sunyer X, Astrup A, Fujioka K, et al. (SCALE). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373:11–22.
• Jastreboff AM, Aronne LJ, Ahmad NN, et al. (SURMOUNT-1). Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205–216.
• Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (SELECT). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389:2221–2232.

Biology of weight regulation

• Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med. 1995;332:621–628.
• Bray GA, Frühbeck G, Ryan DH, Wilding JPH. Management of obesity. Lancet. 2016;387:1947–1956.

National programmes and resources

• Health Promotion Board Singapore. Healthy Weight resources. healthhub.sg
• Healthier SG and Chronic Tier information. healthiersg.gov.sg

This information is for general education only and is not a substitute for medical advice. Medical weight management is individualised — the right combination of lifestyle, medication, and (in selected patients) surgery depends on your specific metabolic picture, comorbidities, preferences, and life circumstances. Please speak with our team. v1.0 · April 2026 · Review due April 2028.